310 related articles for article (PubMed ID: 19526289)
81. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
[TBL] [Abstract][Full Text] [Related]
82. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
[TBL] [Abstract][Full Text] [Related]
83. The mouse MPTP model: gene expression changes in dopaminergic neurons.
Kühn K; Wellen J; Link N; Maskri L; Lübbert H; Stichel CC
Eur J Neurosci; 2003 Jan; 17(1):1-12. PubMed ID: 12534964
[TBL] [Abstract][Full Text] [Related]
84. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
85. Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Selvakumar GP; Janakiraman U; Essa MM; Justin Thenmozhi A; Manivasagam T
Brain Res; 2014 Oct; 1585():23-36. PubMed ID: 24657313
[TBL] [Abstract][Full Text] [Related]
86. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
[TBL] [Abstract][Full Text] [Related]
87. Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Massaquoi MS; Liguore WA; Churchill MJ; Moore C; Melrose HL; Meshul CK
Neuroscience; 2020 May; 433():53-71. PubMed ID: 32142862
[TBL] [Abstract][Full Text] [Related]
88. Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent.
Frau L; Costa G; Porceddu PF; Khairnar A; Castelli MP; Ennas MG; Madeddu C; Wardas J; Morelli M
J Neurochem; 2016 Jan; 136(1):148-62. PubMed ID: 26442661
[TBL] [Abstract][Full Text] [Related]
89. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats.
O'Neill E; Chiara Goisis R; Haverty R; Harkin A
J Neurosci Res; 2019 Jul; 97(7):804-816. PubMed ID: 30924171
[TBL] [Abstract][Full Text] [Related]
90. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.
Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A
Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946
[TBL] [Abstract][Full Text] [Related]
91. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
[TBL] [Abstract][Full Text] [Related]
92. The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice.
El Massri N; Johnstone DM; Peoples CL; Moro C; Reinhart F; Torres N; Stone J; Benabid AL; Mitrofanis J
Int J Neurosci; 2016; 126(1):76-87. PubMed ID: 25469453
[TBL] [Abstract][Full Text] [Related]
93. Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's disease.
Revishchin A; Moiseenko L; Kust N; Bazhenova N; Teslia P; Panteleev D; Kovalzon V; Pavlova G
BMC Neurosci; 2016 Jun; 17(1):34. PubMed ID: 27286696
[TBL] [Abstract][Full Text] [Related]
94. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
McCormack AL; Thiruchelvam M; Manning-Bog AB; Thiffault C; Langston JW; Cory-Slechta DA; Di Monte DA
Neurobiol Dis; 2002 Jul; 10(2):119-27. PubMed ID: 12127150
[TBL] [Abstract][Full Text] [Related]
95. Caffeic acid improves locomotor activity and lessens inflammatory burden in a mouse model of rotenone-induced nigral neurodegeneration: Relevance to Parkinson's disease therapy.
Zaitone SA; Ahmed E; Elsherbiny NM; Mehanna ET; El-Kherbetawy MK; ElSayed MH; Alshareef DM; Moustafa YM
Pharmacol Rep; 2019 Feb; 71(1):32-41. PubMed ID: 30368226
[TBL] [Abstract][Full Text] [Related]
96. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
[TBL] [Abstract][Full Text] [Related]
97. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
98. Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease.
Rodriguez M; Alvarez-Erviti L; Blesa FJ; Rodríguez-Oroz MC; Arina A; Melero I; Ramos LI; Obeso JA
Neurobiol Dis; 2007 Dec; 28(3):316-25. PubMed ID: 17897835
[TBL] [Abstract][Full Text] [Related]
99. Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.
Iravani MM; Sadeghian M; Rose S; Jenner P
J Neural Transm (Vienna); 2014 Dec; 121(12):1493-505. PubMed ID: 24781752
[TBL] [Abstract][Full Text] [Related]
100. Counteracting neuroinflammation in experimental Parkinson's disease favors recovery of function: effects of Er-NPCs administration.
Carelli S; Giallongo T; Gombalova Z; Rey F; Gorio MCF; Mazza M; Di Giulio AM
J Neuroinflammation; 2018 Nov; 15(1):333. PubMed ID: 30501635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
